Altimmune to Present at Upcoming Conferences
GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright Global Life Sciences Conference, being held Mar 9-10, 2021. Also, Altimmune’s Chief Medical Officer, Dr. Scott Harris, will be giving an oral presentation at the 2021 NASH-TAG Conference, being held March 11-13, 2021.
Details on the H.C. Wainwright fireside chat presentation are as follows:
| Title: | H.C. Wainwright Global Life Sciences Conference |
| Presenters: |
Vipin Garg, Ph.D., Chief Executive Officer Scot Roberts, Ph.D., Chief Scientific Officer Scott Harris, M.D., Chief Medical Officer |
| Date/Time: | March 9, 2021 at 7:00 am ET |
A webcast link to the H.C. Wainwright fireside chat presentation will be accessible on the Events section of the Altimmune website.
Details on the NASH-TAG 2021 presentation by Dr. Scott Harris are as follows:
| Title: |
Dual GLP-1 Agonists in the Treatment of Metabolic & Liver Dysfunction in NASH |
| Presenter: |
Scott Harris M.D., Chief Medical Officer |
| Date/Time: |
March 13, 2021 at 9:30 pm ET |
A copy of the presentation materials will be accessible on the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
Investor & Media Contacts:
| Will Brown | Stacey Jurchison |
| Chief Financial Officer | Sr. Dir, Investor Relations |
| Phone: 240-654-1450 | Phone : 410-474-8200 |
| wbrown@altimmune.com | sjurchison@altimmune.com |
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
